AI Article Synopsis

  • The autotransporter protein secretion system effectively targets the secretion of challenging recombinant proteins, like IrmA, to avoid toxicity associated with intracellular production.
  • IrmA, a vaccine candidate, was successfully produced using a plasmid that allowed its secretion into the culture supernatant, yielding 29.3 mg/L under scaled-up conditions.
  • This method not only achieved comparable quality to traditional cytoplasmic production but also has the potential to streamline processing steps, reducing costs and development time in the biotechnology industry.

Article Abstract

The autotransporter protein secretion system has been used previously to target the secretion of heterologous proteins to the bacterial cell surface and the extracellular milieu at the laboratory scale. The platform is of particular interest for the production of "difficult" recombinant proteins that might cause toxic effects when produced intracellularly. One such protein is IrmA. IrmA is a vaccine candidate that is produced in inclusion bodies requiring refolding. Here, we describe the use and scale-up of the autotransporter system for the secretion of an industrially relevant protein (IrmA). A plasmid expressing IrmA was constructed such that the autotransporter platform could secrete IrmA into the culture supernatant fraction. The autotransporter platform was suitable for the production and purification of IrmA with comparable physical properties to the protein produced in the cytoplasm. The production of IrmA was translated to scale-up protein production conditions resulting in a yield of 29.3 mg/L of IrmA from the culture supernatant, which is consistent with yields of current industrial processes. Recombinant protein production is an essential component of the biotechnology sector. Here, we show that the autotransporter platform is a viable method for the recombinant production, secretion, and purification of a "difficult" to produce protein on an industrially relevant scale. Use of the autotransporter platform could reduce the number of downstream processing operations required, thus accelerating the development time and reducing costs for recombinant protein production.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269718PMC
http://dx.doi.org/10.1128/spectrum.03594-22DOI Listing

Publication Analysis

Top Keywords

autotransporter platform
16
recombinant protein
12
protein production
12
protein
9
secretion heterologous
8
irma
8
protein irma
8
industrially relevant
8
irma culture
8
culture supernatant
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!